2020 Outlook on the Global Acromegaly Market - Epidemiology Forecast to 2030 - ResearchAndMarkets.com

The "Acromegaly - Epidemiology Forecast to 2030" report has been added to ResearchAndMarkets.com's offering.

This report delivers an in-depth understanding of the Acromegaly, historical and forecasted epidemiology as well as the Acromegaly trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

Reasons to Buy

1. Develop business strategies by understanding the trends shaping and driving the 7MM Acromegaly epidemiology forecast.
2. The Acromegaly epidemiology report and model were written and developed by Masters and Ph.D. level epidemiologists.
3. The proprietary Acromegaly epidemiology model is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over the eleven-year forecast period using reputable sources.

Acromegaly Epidemiology Perspective

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Prevalent Cases of Acromegaly, Total Diagnosed Prevalent Cases of Acromegaly, Origin Specific Cases of Acromegaly, and Diagnosed Cases of Acromegaly Based on Type of Adenomas scenario of Acromegaly in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom) and Japan from 2017 to 2030.

Acromegaly Detailed Epidemiology Segmentation

• As per the analysis, the prevalent cases in the 7MM were 64,508 in 2017.
• The diagnosed patient pool in the 7MM comprised 49,814 patients in 2017.
• In the case of the United States, the prevalent population was estimated to be 28,671 cases in 2017.
• In the US, the diagnosed cases of Acromegaly based on types of Adenomas were 18,349 of macroadenomas and 4,587 of microadenomas in 2017.
• In the Origin based segmentation of Acromegaly in 2017, 21,790 cases were originated at the Pituitary Tumor and the remaining 1,147 Acromegaly cases were from Non-Pituitary Tumor, in the US.
• In the EU5, the highest prevalent cases were reported to be in Germany followed by the United Kingdom and France whereas the lowest prevalence rates were reported in Spain from 2017 through 2030
• Japan was reported to have 10,690 prevalent cases in 2017.

Scope of the Report

• The report covers the descriptive overview of Acromegaly, explaining its etiology, signs and symptoms, pathophysiology, genetic basis, and currently available therapies.
• The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom) and Japan.
• The report assesses the disease risk and burden and highlights the unmet needs of Acromegaly.
• The report helps to recognize the growth opportunities in the 7MM with respect to the patient population.
• The report provides the segmentation of the disease epidemiology for 7MM by Total Prevalent Cases of Acromegaly, Total Diagnosed Prevalent Cases of Acromegaly, Origin Specific Cases of Acromegaly, and Diagnosed Cases of Acromegaly Based on Type of Adenomas.

Key Questions Answered

• What is the disease risk, burden and unmet needs of Acromegaly?
• What is the historical Acromegaly patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK) and Japan?
• What would be the forecasted patient pool of Acromegaly at the 7MM level?
• What will be the growth opportunities across the 7MM with respect to the patient population pertaining to Acromegaly?
• Out of the above-mentioned countries, which country would have the highest prevalent population of Acromegaly during the forecast period (2020-2030)?
• At what CAGR the population is expected to grow across the 7MM during the forecast period (2020-2030)?

Key Topics Covered:

1. Key Insights

2. Executive Summary

3. Acromegaly Epidemiology Overview at a Glance

3.1. Epidemiology (%) Distribution of Acromegaly in 2017

3.2. Epidemiology (%) Distribution of Acromegaly in 2030

4. Acromegaly (ACM): Disease Overview

4.1. Introduction

4.2. Signs and Symptoms

4.3. Classification of Pituitary Adenomas

4.4. Clinical Manifestations of Acromegaly

4.5. Etiology

4.6. Pathophysiology

4.7. Genetic Bases of Acromegaly

4.8. Pathogenesis

4.9. Diagnosis

4.9.1. Diagnosis Guidelines

4.9.2. Endocrine Society Clinical Practice Guideline - United Kingdom

4.9.3. American Association of Clinical Endocrinologists (AACE) - USA

5. Epidemiology and Patient Population

5.1. Key Findings

5.2. Methodology

5.3. Total Prevalent Cases of Acromegaly in the 7MM

5.4. Total Diagnosed Cases of Acromegaly in the 7MM

6. United States Epidemiology

7. EU5 Epidemiology

8. Japan Epidemiology

9. Appendix

10. Analyst Capabilities

11. Disclaimer

12. About the Publisher

For more information about this report visit https://www.researchandmarkets.com/r/lsu5ia

View source version on businesswire.com: https://www.businesswire.com/news/home/20201016005484/en/